Improved overall survival of metastatic cancers in the United States across all age groups in the immunotherapy era: Implications for considering elderly patients (age ≥ 75) for immune checkpoint inhibitors (ICIs)

MLA

Yu-Wei Chen, et al. “Improved Overall Survival of Metastatic Cancers in the United States across All Age Groups in the Immunotherapy Era: Implications for Considering Elderly Patients (Age ≥ 75) for Immune Checkpoint Inhibitors (ICIs).” Journal of Clinical Oncology, vol. 40, June 2022, p. 12039. EBSCOhost, https://doi.org/10.1200/jco.2022.40.16_suppl.12039.

APA

Yu-Wei Chen, Matthew D Tucker, Hesham Abdallah Yasin, Xingyi Guo, Xiao-Ou Shu, & Brian I. Rini. (2022). Improved overall survival of metastatic cancers in the United States across all age groups in the immunotherapy era: Implications for considering elderly patients (age ≥ 75) for immune checkpoint inhibitors (ICIs). Journal of Clinical Oncology, 40, 12039. https://doi.org/10.1200/jco.2022.40.16_suppl.12039

Chicago

Yu-Wei Chen, Matthew D Tucker, Hesham Abdallah Yasin, Xingyi Guo, Xiao-Ou Shu, and Brian I. Rini. 2022. “Improved Overall Survival of Metastatic Cancers in the United States across All Age Groups in the Immunotherapy Era: Implications for Considering Elderly Patients (Age ≥ 75) for Immune Checkpoint Inhibitors (ICIs).” Journal of Clinical Oncology 40 (June): 12039. doi:10.1200/jco.2022.40.16_suppl.12039.